The most award winning
healthcare information source.
TRUSTED FOR FOUR DECADES.
By Leslie Coplin, Executive Editor
Increasingly, use of tissue plasminogen activator (tPA) for treating ischemic stroke continues to rise. But minorities, women, and residents of the “stroke belt,” a group of 11 southeastern states, are left behind when it comes to receiving this FDA-approved treatment that can dissolve clots and restore blood flow to the brain if administered within 4.5 hours of the first symptoms of stroke, according to researchers at the American Stroke Association’s 2017 International Stroke Conference.
National efforts by hospitals, government agencies, and professional organizations aim to increase the number of patients who receive tPA. Tracy Madsen, MD, ScM, at Brown University, led a team of researchers who reviewed records from the National Inpatient Sample to determine if quality improvement efforts to increase tPA use are effective. They found that blacks and Hispanics were less likely to receive tPA than whites, and women were less likely than men to receive tPA. In addition, patients with Medicare were less likely to receive tPA than those with private insurance, and residents of the “stroke belt” were less likely to receive tPA than patients in other regions.
Some previous studies have found that up to three-fourths of patients arrived after the time window for tPA had closed,” Madsen said in a release. “Many patients across all groups do not arrive at the hospital in time, but this is particularly true for underrepresented minorities.”
For complete coverage of the International Stroke Conference, please see the April 2017 issue of Neurology Alert. More than 4,100 healthcare professionals from 60 countries met at ISC 2017 in Houston to participate in educational sessions on the latest science in stroke research.